Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Moderna's 4Q Results Impacted by Drop in COVID Vax Sales | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Moderna’s 4Q Results Impacted by Drop in COVID Vax Sales

Product sales for the quarter were down 30%, primarily driven by lower sales volume and the related manufacturing ramp up in 4Q21.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Moderna
4Q Revenues: $5.1 billion (-29%)
4Q Earnings: $1.5 billion (-70%)
FY Revenues: $19.3 billion (-4%)
FY Earnings: $8.4 billion (-31%)
Comments: Results in the quarter impacted by a decrease in COVID-19 vaccines sales. Product sales for the quarter were $4.9 billion, down 30%, primarily driven by lower sales volume and the related manufacturing ramp up in 4Q21.
 
Spikevax Bivalent BA.4/BA.5 authorized under EUA in the U.S. as a booster dose for all age groups from 5 months. Moderna will file for regulatory approval for mRNA-1345, an investigational RSV vaccine for older adults, in 1H23. mRNA-1345 was recently granted FDA Breakthrough Therapy Designation. mRNA-4157, the company’s investigational personalized cancer vaccine in combination with Merck’s Keytruda, was granted Breakthrough Therapy Designation.
 
R&D expenses for the quarter increased by 87% to $1.2 billion, mainly due to an increase in clinical trial-related expenses, particularly with respect to RSV, seasonal flu and CMV programs.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters